August 6, 2020 -- Cellect Biotechnology has secured a European patent for its stem cell selection technology. The patent was also approved in Australia and Israel, according to the firm.
European patent No. 14851547.1 will expire in October 2034. It covers the regenerative capacity of stem and progenitor cells in the company's Apograft cell-based blood product. Importantly, it protects the intellectual property of the second component of Apograft involving the activation of stem and progenitor cells.
Cellect currently holds 45 patents, it said.